Search

everythinglearnresearchcommunity

for

Search:↓

The antibody 005-C04 blocks prolactin receptors, causing reversible infertility, impaired lactation, and hair regrowth in female mice.

Canakinumab's effect on COVID-19 outcomes is unclear.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.

Adalimumab may cause severe hair loss in some patients.

Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.

Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.

A woman developed hair loss after starting a treatment with adalimumab, suggesting this medication might cause hair loss.

BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

A patient with PPP had rare skin reactions to adalimumab, which improved after stopping smoking and continuing acitretin.

Omalizumab may cause hair loss.

Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.

A woman with rheumatoid arthritis lost all her hair during adalimumab treatment, and stopping the drug didn't help.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.

Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.

Ocrelizumab may cause delayed hair loss in some patients.

Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.

Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.

CD28 is a promising target for treating alopecia areata with belatacept.

CD28 is a promising target for treating alopecia areata with belatacept.

Psoriasis involves an imbalance between certain immune cells, and targeting these could help restore skin health.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

Adalimumab can cause hair loss and scalp issues in some psoriasis patients.

Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.